Aurobindo Pharma receives USFDA approval for Azithromycin oral suspension

Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration to manufacture and market Azithromycin oral suspension 100 mg/5 mL and 200 mg/5 mL. Azithromycin oral suspension is a generic version of Pfizer Inc’s Zithromax oral suspension. The product will be launched in November 2018, the company said in a filing with BSE. Azithromycin oral suspension is indicated for the treatment of patients with mild to moderate infections. The approved product has an estimated market size of USD 71 million for the twelve months ending August 2018, according to IQVIA.